


EGCG-4''-sulfate

Cat. No.:	HY-150526
CAS No.:	2708237-76-5
Molecular Formula:	C ₂₂ H ₁₈ O ₁₄ S
Molecular Weight:	538.43
Target:	Endogenous Metabolite; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EGCG-4''-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4''-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma ^{[1][2][3][4]} .														
In Vitro	<p>EGCG-4''-sulfate (10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner^[1].</p> <p>EGCG-4''-sulfate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression^[1].</p> <p>EGCG-4''-sulfate (10-60 μM, 12 h) reduces cell motility and migration^[1].</p> <p>EGCG-4''-sulfate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)^[2].</p> <p>EGCG-4''-sulfate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase^[3].</p> <p>EGCG-4''-sulfate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>FB-2 and WRO cells (serum-starved for 48h)</td> </tr> <tr> <td>Concentration:</td> <td>10, 40, 60 μM.</td> </tr> <tr> <td>Incubation Time:</td> <td>4 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>FB-2 cells</td> </tr> <tr> <td>Concentration:</td> <td>10, 40, 60 μM.</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> </table>	Cell Line:	FB-2 and WRO cells (serum-starved for 48h)	Concentration:	10, 40, 60 μM.	Incubation Time:	4 days	Result:	Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).	Cell Line:	FB-2 cells	Concentration:	10, 40, 60 μM.	Incubation Time:	24 h
Cell Line:	FB-2 and WRO cells (serum-starved for 48h)														
Concentration:	10, 40, 60 μM.														
Incubation Time:	4 days														
Result:	Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).														
Cell Line:	FB-2 cells														
Concentration:	10, 40, 60 μM.														
Incubation Time:	24 h														

Result:	Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2. Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α 5-integrin.
---------	---

Cell Migration Assay ^[1]

Cell Line:	FB-2 and WRO cells (serum-starved for 48h)
Concentration:	10, 40, 60 μ M.
Incubation Time:	12 h
Result:	Reduced migration activity in FB-2 and WRO cells.

RT-PCR^[4]

Cell Line:	Mouse primary osteoblasts (1 ng/ml LPS-treated)
Concentration:	30 μ M
Incubation Time:	3, 6, 12, 24 h
Result:	Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.

In Vivo

EGCG-4''-sulfate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth^[3].

EGCG-4''-sulfate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Orthotopic transplant BALB/c nude mice model ^[3]
Dosage:	5, 10, and 20 mg/kg, once daily for 14 days.
Administration:	Intragastrical administration.
Result:	Inhibited tumors growth with no liver or lung metastases.

Animal Model:	Model of experimental periodontitis, LPS (25 μ g/mouse) ^[4]
Dosage:	0.5 mg/mouse, a single dose.
Administration:	Injected into the mouse lower gingiva
Result:	Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.

REFERENCES

- [1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. *J Cell Physiol.* 2013 Apr 1.
- [2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. *Cancer Metab.* 2019 May 20;7:4.
- [3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. *Onco Targets Ther.* 2013;6:145-53.

[4]. Tsukasa Tominari, et al; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA